Home > Oncology > BCC 2019 > Selected Posters > New Prognostic Biomarkers for Survival Breast Cancer

New Prognostic Biomarkers for Survival Breast Cancer

Presented By
Dr Jasmin Zeindler, University Hospital Basel, Switzerland
BCC 2019

Tailored therapy of patients with breast cancer - to avoid overtreatment as well as undertreatment - is dependent on the availability of prognostic and predictive biomarkers. Dr Jasmin Zeindler (University Hospital Basel, Switzerland) and colleagues presented two new prognostic biomarkers associated with survival: nectin-4 expression on triple-negative breast cancer cells and tumour infiltration by myeloperoxidase neutrophilic cells [1,2].

Triple-negative breast cancer represents about 10–20% of all invasive breast cancers and is associated with a poor prognosis. The nectin cell-adhesion protein 4 (nectin-4) is a junction protein involved in the formation and maintenance of cell junctions. Nectin-4 has previously shown to be expressed in about 60% of triple-negative breast cancer cells as well as in triple-negative breast cancer metastases, but to be absent in normal breast tissue, which makes it a potential specific target for triple-negative breast cance...

please login to read the entire article:

You need to register to read the entire article, please do so now.

Posted on